Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis.
O'Muircheartaigh J, Vavasour I, Ljungberg E, Li DKB, Rauscher A, Levesque V, Garren H, Clayton D, Tam R, Traboulsee A, Kolind S. O'Muircheartaigh J, et al. Among authors: levesque v. Hum Brain Mapp. 2019 May;40(7):2104-2116. doi: 10.1002/hbm.24510. Epub 2019 Jan 15. Hum Brain Mapp. 2019. PMID: 30648315 Free PMC article. Clinical Trial.
Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.
MacMillan EL, Schubert JJ, Vavasour IM, Tam R, Rauscher A, Taylor C, White R, Garren H, Clayton D, Levesque V, Li DK, Kolind SH, Traboulsee AL. MacMillan EL, et al. Among authors: levesque v. Mult Scler J Exp Transl Clin. 2019 Oct 15;5(4):2055217319879952. doi: 10.1177/2055217319879952. eCollection 2019 Oct-Dec. Mult Scler J Exp Transl Clin. 2019. PMID: 31662881 Free PMC article.
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Hauser SL, et al. Among authors: levesque v. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20. Neurology. 2020. PMID: 32690791 Free PMC article.
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Ponikowski P, et al. Among authors: levesque v. Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31. Eur Heart J. 2015. PMID: 25176939 Free PMC article. Clinical Trial.
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh TA, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Ponikowski P, et al. Among authors: levesque v. ESC Heart Fail. 2014 Sep;1(1):52-58. doi: 10.1002/ehf2.12006. ESC Heart Fail. 2014. PMID: 28834668 Free article.
61 results